Dow Drops Over 100 Points; U.S. Trade Deficit Shrinks To This Level In June
U.S. stocks traded lower this morning, with the Dow Jones falling more than 100 points on Thursday.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
ChemoCentryx Reports Safety Results Available From Ongoing Phase I Trial Of Orally Administered PD-L1 Inhibitor, CCX559, At ASCO 2022 Annual Meeting
ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company's highly potent, orally administered PD-L1 checkpoint
55 Stocks Moving In Friday’s Mid-Day Session
Gainers
Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
Raymond James Maintains Strong Buy on ChemoCentryx, Lowers Price Target to $106
Raymond James analyst Steven Seedhouse maintains ChemoCentryx (NASDAQ:CCXI) with a Strong Buy and lowers the price target from $110 to $106.
24 Stocks Moving in Friday’s Pre-Market Session
Gainers
Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 35% to $3.47 in pre-market trading. Vinco Ventures set record date as May 18, 2022 For dividend of shares related to Cryptyde deal. The dividend is expected to be distributed on May 27, 2022.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
ChemoCentryx’s Earnings: A Preview
ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that ChemoCentryx will report an earnings per share (EPS) of $-0.30.